Efficacy and safety of cladribine, low-dose cytarabine and venetoclax in newly diagnosed and relapsed/refractory acute myeloid leukemia: results of a single center study
Annals of Hematology · 2025
DOI: 10.1007/s00277-025-06389-9 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Hematology, 2025. Verfasst von Ting Zhu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Anhui Provincial Hospital Affiliated to Anhui Medical University, Hefei, People's Republic of China. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Cytarabine, Sulfonamides, Cladribine. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
The aim of this study was to assess the safety, response, and survival outcomes of cladribine (CLAD) + low-dose cytarabine (LDAC) + venetoclax (CAV) in patients with relapsed/refractory (R/R) and newly diagnosed acute myeloid leukemia (AML). This single-center, retrospective, non-randomized study included 46 adult patients with 29 R/R AML and 17 newly diagnosed AML who were unfit for intensive chemotherapy. All patients received the CAV regimen at our center. In the R/R group (median age 55 years, range 21-77), complete response (CR) was achieved in 44.8%, CR with incomplete blood count recovery (CRi) in 24.1%, composite complete remission (CRc, CR + CRi) and measurable residual disease (MRD) negativity in 51.7%. The median follow-up was 10.9 months, with median overall survival (OS) of 16.4 months (95% CI, 10.9-21.8). Leukopenia (62.1%) was the most common hematologic toxicity, and infection (44.8%) was the most common non-hematologic toxicity. The 30-day mortality rate was 0%, and one patient died within 60 days. In the newly diagnosed group, CR was 76.5%, CRi 17.6%, CRc 94.1%, and MRD negativity 82.3% after one induction cycle. The median OS was 15.5 months (95% CI, 11.1-19.9). Common grade 3/4 hematologic toxicities were leukopenia (76.5%), with infection (52.9%) as the most common non-hematologic toxicity. The CAV regimen demonstrated a high CRc rate and MRD negativity in R/R AML with manageable toxicity. In newly diagnosed acute myeloid leukaemia, this regimen has also demonstrated favourable efficacy, as previously reported, with tolerable haematological toxicity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Anhui Provincial Hospital Affiliated to Anhui Medical University, Hefei, People's Republic of China.
- Department of Hematology, Division of Life Sciences and Medicine, The First Affiliated Hospital of USTC, University of Science and Technology of China, Hefei, Anhui, 230001, China.
- Department of Hematology, Anqing Hospital Affiliated to Anhui Medical University, Anqing, Anhui, 246000, China. danielxu9@163.com.
- Department of Hematology, Division of Life Sciences and Medicine, The First Affiliated Hospital of USTC, University of Science and Technology of China, Hefei, Anhui, 230001, China. way0623@ustc.edu.cn.
- Department of Hematology, Anhui Provincial Hospital Affiliated to Anhui Medical University, Hefei, People's Republic of China. lxinahf@sina.com.
Zitieren
APA
Zhu, T., Wang, L., Jiang, H., Huang, S., Xu, H., Wang, A., & Liu, X. (2025). Efficacy and safety of cladribine, low-dose cytarabine and venetoclax in newly diagnosed and relapsed/refractory acute myeloid leukemia: results of a single center study. Annals of Hematology. https://doi.org/10.1007/s00277-025-06389-9
Vancouver
Zhu T, Wang L, Jiang H, Huang S, Xu H, Wang A, et al. Efficacy and safety of cladribine, low-dose cytarabine and venetoclax in newly diagnosed and relapsed/refractory acute myeloid leukemia: results of a single center study. Annals of Hematology. 2025. doi:10.1007/s00277-025-06389-9
BibTeX
@article{Zhu2025,
author = {Zhu, Ting and Wang, Li and Jiang, Hui and Huang, Shujuan and Xu, Haitao and Wang, Anyou and Liu, Xin},
title = {Efficacy and safety of cladribine, low-dose cytarabine and venetoclax in newly diagnosed and relapsed/refractory acute myeloid leukemia: results of a single center study},
journal = {Annals of Hematology},
year = {2025},
doi = {10.1007/s00277-025-06389-9}
}
EUVIMED